Botulism classification

Botulism Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Botulism from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Botulism classification On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Botulism classification All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Botulism classification
CDC on Botulism classification
Botulism classification in the news
Blogs on Botulism classification
Directions to Hospitals Treating Botulism
Risk calculators and risk factors for Botulism classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Michael Maddaleni, B.S., Keanu Ngo[2]

Overview

Botulism is classified along two complementary axes: (1) the route by which botulinum neurotoxin (BoNT) reaches the circulation (transmission category), which determines epidemiology, diagnostic sampling, and public-health response; and (2) the BoNT serotype and the neurotoxigenic Clostridium species that produced it, which determines antitoxin coverage and laboratory confirmation. All forms share an identical final clinical syndrome—symmetric cranial-nerve palsies followed by descending, symmetric flaccid paralysis with preserved sensorium—because the toxin's mechanism at the neuromuscular junction is the same regardless of route.

Classification by route of toxin acquisition

Naturally occurring forms

Four naturally occurring forms are recognized, distinguished by whether preformed toxin is ingested versus produced in situ by colonizing organisms:

• Infant botulism — intestinal colonization by ingested spores, with germination and in situ toxin production in infants younger than 12 months (predominantly <6 months). It is the most common form in the United States. Honey is an avoidable but uncommon identified source; most cases involve environmental spore exposure (soil, dust) rather than a specific food.
• Foodborne botulism — ingestion of preformed toxin from food in which spores germinated and produced toxin under anaerobic, low-acid, low-salt/low-sugar conditions. Home-canned/preserved vegetables and fermented fish are classic vehicles; commercially processed foods and prison-made wine (“pruno”) are less common sources.
• Wound botulism — wound contamination, germination, and in situ toxin production. Most modern cases arise from injection drug use (“skin popping,” black-tar heroin); gross trauma or crush injury is a less common predisposing event. It is not the rarest form. Fever may be present when the wound is secondarily infected, unlike other forms.
• Adult intestinal colonization (toxemia) botulism — the adult/older-child analogue of infant botulism, in which ingested spores colonize the intestine and produce toxin in situ. It is exceedingly rare and typically requires a predisposing alteration of gut anatomy or flora—prior bowel or gastric surgery, short-bowel syndrome, inflammatory bowel disease/Crohn disease, anatomical bowel abnormalities, or recent antimicrobial therapy.

Incubation periods differ by form and aid classification: foodborne botulism typically 12–48 hours (range 6 hours–10 days), infant botulism an estimated 3–30 days, and wound botulism 4–14 days from injury.

The mechanistic dividing line is diagnostically important: foodborne botulism involves ingested preformed toxin (no ongoing intestinal production), whereas infant and adult intestinal colonization botulism involve ongoing in situ production, so neurotoxigenic clostridia may be shed in stool for weeks.

Non-naturally occurring forms

• Iatrogenic botulism — systemic weakness following injection of excess therapeutic or cosmetic BoNT (e.g., for dystonia, spasticity, migraine, or cosmesis).
• Inhalational botulism — results from aerosolized toxin; it does not occur naturally and is chiefly relevant as a bioterrorism scenario. BoNT is a CDC Category A bioterrorism agent.

A useful mnemonic distinction: infant, foodborne, and adult intestinal forms enter via the gastrointestinal route; wound via tissue; and iatrogenic/inhalational via injection or aerosol.

Classification by neurotoxin serotype and producing organism

BoNTs are divided into seven classical immunologically distinct serotypes (BoNT/A–G), further resolved into more than 40 subtypes by amino-acid sequence variation within the bont gene. Newer literature describes additional or novel toxin types beyond the classical seven—including the chimeric BoNT/HA (also called type H or F/A), BoNT/X, and a toxin encoded by Enterococcus (eBoNT/J)—and some recent sources therefore cite up to nine serotypes (A–H and X); the classical A–G framework remains standard for clinical purposes.

• Serotypes causing human disease: A, B, E, and F. Serotypes A and B are the most prevalent in the United States.
• Producing organisms: most disease is caused by Clostridium botulinum, but neurotoxigenic strains of C. butyricum (typically type E) and C. baratii (typically type F) produce clinically identical illness. Type F C. baratii is a recognized cause of both infant botulism and adult intestinal toxemia botulism.

Serotype matters for treatment-product selection: human-derived BIG-IV (BabyBIG) covers toxin types A and B, whereas equine heptavalent antitoxin (HBAT) covers serotypes A–G (see Medical therapy).

Clinically actionable points

• Establish the transmission category early, because it dictates specimen collection (stool/enema for colonization forms; serum for all; wound culture for wound botulism; implicated food for foodborne) and public-health actions.
• Do not withhold antitoxin while awaiting serotype identification; product choice depends on the clinical form and age, and treatment is time-critical.
• Consider adult intestinal colonization botulism in a patient with the classic syndrome, no food or wound source, and a predisposing gut condition.